Loading
A phase 1/2 trial of Spevatamig, Paclitaxel / nab-paclitaxel, Gemcitabine in pancreatic ductal adenocarcinoma, run by Phanes Therapeutics, now recruiting.
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) is a phase 1/2 interventional study registered as NCT05482893 by Phanes Therapeutics, with 258 participants planned, started 2023-03-15 and due to reach its primary completion in 2027-12. Interventions recorded: Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab). Conditions listed: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC). No results are recorded here; the registry entry is the source.
Shares Phanes Therapeutics, Paclitaxel / nab-paclitaxel, Gemcitabine, Metastatic pancreatic ductal adenocarcinoma.
Shares Phanes Therapeutics, Pancreatic ductal adenocarcinoma.
Shares CAPOX (capecitabine, oxaliplatin), Paclitaxel / nab-paclitaxel, Gemcitabine, Metastatic pancreatic ductal adenocarcinoma.
Shares CAPOX (capecitabine, oxaliplatin), FOLFOX (5-FU, leucovorin, oxaliplatin), Pancreatic ductal adenocarcinoma.
Shares CAPOX (capecitabine, oxaliplatin), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares CAPOX (capecitabine, oxaliplatin), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.